Analysts Set Expectations for SCYNEXIS FY2026 Earnings

SCYNEXIS, Inc. (NASDAQ:SCYX) – Brookline Capital Acquisition lowered their FY2026 earnings per share estimates for SCYNEXIS in a research report issued on Monday, March 9th. Brookline Capital Acquisition analyst K. Dolliver now forecasts that the company will post earnings per share of ($0.34) for the year, down from their prior estimate of $1.03. Brookline Capital Acquisition has a “Buy” rating on the stock. Brookline Capital Acquisition also issued estimates for SCYNEXIS’s FY2027 earnings at ($0.20) EPS, FY2028 earnings at ($0.29) EPS and FY2029 earnings at ($0.62) EPS.

SCYNEXIS (NASDAQ:SCYX) last posted its quarterly earnings data on Wednesday, March 4th. The company reported $0.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.04). The company had revenue of $17.20 million for the quarter, compared to analysts’ expectations of $8.10 million. SCYNEXIS had a negative return on equity of 25.52% and a negative net margin of 41.79%.

Several other equities analysts also recently commented on SCYX. Weiss Ratings reiterated a “sell (d-)” rating on shares of SCYNEXIS in a research note on Monday, December 29th. Wall Street Zen raised SCYNEXIS from a “hold” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, SCYNEXIS currently has an average rating of “Hold” and an average price target of $3.00.

SCYNEXIS Stock Down 0.8%

SCYNEXIS stock opened at $0.89 on Thursday. The firm has a 50 day moving average price of $0.74 and a 200-day moving average price of $0.75. SCYNEXIS has a twelve month low of $0.57 and a twelve month high of $1.31. The company has a market capitalization of $39.84 million, a P/E ratio of -5.25 and a beta of 1.33.

Institutional Trading of SCYNEXIS

Institutional investors have recently modified their holdings of the business. Jane Street Group LLC bought a new position in SCYNEXIS in the 2nd quarter worth approximately $27,000. Sequoia Financial Advisors LLC purchased a new stake in shares of SCYNEXIS during the third quarter worth $41,000. GSA Capital Partners LLP lifted its position in shares of SCYNEXIS by 95.2% during the third quarter. GSA Capital Partners LLP now owns 104,423 shares of the company’s stock worth $80,000 after acquiring an additional 50,916 shares in the last quarter. Bridgeway Capital Management LLC boosted its holdings in shares of SCYNEXIS by 4.2% in the second quarter. Bridgeway Capital Management LLC now owns 368,180 shares of the company’s stock worth $248,000 after acquiring an additional 14,689 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of SCYNEXIS by 7.1% in the fourth quarter. Geode Capital Management LLC now owns 449,223 shares of the company’s stock worth $284,000 after acquiring an additional 29,775 shares during the period. 54.37% of the stock is currently owned by hedge funds and other institutional investors.

SCYNEXIS News Roundup

Here are the key news stories impacting SCYNEXIS this week:

• Positive Sentiment: Brookline raised multi‑year estimates and keeps a Buy — The firm improved FY2027, FY2028 and FY2029 EPS projections (FY2027 to ($0.20) from ($0.48); FY2028 to ($0.29) from ($0.30); FY2029 to ($0.62) from ($0.64)) and continues to rate SCYNEXIS a “Buy.” These upward tweaks for later-year estimates may support a more constructive medium-term story for the stock.
• Positive Sentiment: Clinical progress — First participants dosed in the Phase 1 single-ascending and multiple-ascending dose trial of IV SCY-247, SCYNEXIS’s second‑generation triterpenoid antifungal. Early clinical milestones reduce binary trial risk in the near term and can be a catalyst if safety and PK readouts are positive. Phase 1 dosing announcement
• Neutral Sentiment: Quarterly & long‑range forecasts published — Brookline released Q1–Q4 2026 quarterly EPS estimates (generally around ($0.10) per quarter, Q4 at ($0.05)) and a FY2030 projection of $0.46 EPS. These provide a structured roadmap for expectations but are distant and depend on pipeline progress and financing, so impact is uncertain.
• Negative Sentiment: Material near‑term cut for FY2026 — Brookline sharply reduced its FY2026 EPS forecast to ($0.34) from a prior $1.03. That large downward revision signals a weaker near-term profitability/cash-flow outlook than previously modeled and likely explains downward pressure on the stock today.

SCYNEXIS Company Profile

SCYNEXIS, Inc is a late‐stage biopharmaceutical company focused on developing and commercializing novel anti‐infective therapies. Headquartered in Jersey City, New Jersey, the company’s primary research and development efforts center on combating invasive and chronic fungal infections, an area of high unmet medical need. SCYNEXIS’s scientific platform is built around its proprietary triterpenoid class of antifungals, which are designed to address resistance and safety limitations associated with existing treatments.

The company’s lead product candidate, ibrexafungerp, represents the first oral glucan synthase inhibitor to reach clinical development.